BIOMAT Database Logo BIOMAT Database Logo

Comparison of diagnostic criteria of IGT, borderline, and GDM. Blood glucose curve and IRI response. 1991

Y Omori, and S Minei, and Y Uchigata, and M Shimizu, and M Sanaka, and M Honda, and Y Hirata
Diabetes Center, Tokyo Women's Medical College, Japan.

A 75-g oral glucose tolerance test (OGTT) was performed in 615 nonobese pregnant women (mean +/- SD age 29.7 +/- 4.3 yr) who were referred to the Division of Internal Medicine at our diabetes center because of glycosuria. Seventy-seven cases were found to have urinary glucose at the first trimester, 185 at the second trimester, and 353 at the third trimester. With their 75-g OGTT results, the diagnostic criteria of borderline (formulated by the Japan Diabetes Society), impaired glucose tolerance (IGT; defined by the World Health Organization [WHO]), and gestational diabetes mellitus (GDM; determined by the Japan Society of Obstetrics & Gynecology standards) were compared through blood glucose (BG) curves and immunoreactive insulin (IRI) responses. Borderline (fasting BG greater than or equal to 6.1 and less than 7.8 mM and 2-h BG greater than or equal to 6.7 and less than 11.1 mM) is neither diabetes nor normal. IGT is as referred to by the WHO. GDM exceeds two points of fasting BG greater than or equal to 5.6 mM, 1-h BG greater than or equal to 10.0 mM, or 2-h BG greater than or equal to 8.3 mM. Diabetes mellitus (DM) is as referred to by the Japan Diabetes Society (same as the WHO). The prevalence of abnormal glucose tolerance among all 615 pregnant women was 54.6% in borderline, 24.5% in IGT, 7.3% in GDM, and 3.4% in DM. The 2-h BG levels in IGT during the first trimester were higher than in borderline (P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D011236 Prediabetic State The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2). Prediabetes,Prediabetic States,State, Prediabetic,States, Prediabetic
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011248 Pregnancy Complications Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases. Adverse Birth Outcomes,Complications, Pregnancy,Adverse Birth Outcome,Birth Outcome, Adverse,Complication, Pregnancy,Outcome, Adverse Birth,Pregnancy Complication
D011261 Pregnancy Trimester, First The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation. Early Placental Phase,Pregnancy, First Trimester,Trimester, First,Early Placental Phases,First Pregnancy Trimester,First Pregnancy Trimesters,First Trimester,First Trimester Pregnancies,First Trimester Pregnancy,First Trimesters,Phase, Early Placental,Phases, Early Placental,Placental Phase, Early,Placental Phases, Early,Pregnancies, First Trimester,Pregnancy Trimesters, First,Trimesters, First
D011262 Pregnancy Trimester, Second The middle third of a human PREGNANCY, from the beginning of the 15th through the 28th completed week (99 to 196 days) of gestation. Midtrimester,Pregnancy, Second Trimester,Trimester, Second,Midtrimesters,Pregnancies, Second Trimester,Pregnancy Trimesters, Second,Second Pregnancy Trimester,Second Pregnancy Trimesters,Second Trimester,Second Trimester Pregnancies,Second Trimester Pregnancy,Second Trimesters,Trimesters, Second
D011263 Pregnancy Trimester, Third The last third of a human PREGNANCY, from the beginning of the 29th through the 42nd completed week (197 to 294 days) of gestation. Pregnancy, Third Trimester,Trimester, Third,Last Trimester,Last Trimesters,Pregnancies, Third Trimester,Pregnancy Trimesters, Third,Third Pregnancy Trimester,Third Pregnancy Trimesters,Third Trimester,Third Trimester Pregnancies,Third Trimester Pregnancy,Third Trimesters,Trimester, Last,Trimesters, Last,Trimesters, Third
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005260 Female Females

Related Publications

Y Omori, and S Minei, and Y Uchigata, and M Shimizu, and M Sanaka, and M Honda, and Y Hirata
Heterogeneity of plasma IRI responses in patients with IGT.
August 1980, Diabetologia,
Y Omori, and S Minei, and Y Uchigata, and M Shimizu, and M Sanaka, and M Honda, and Y Hirata
Heterogeneity of plasma IRI responses in patients with IGT.
April 1980, Diabetologia,
Y Omori, and S Minei, and Y Uchigata, and M Shimizu, and M Sanaka, and M Honda, and Y Hirata
Duplication of the blood glucose curve of an OGTT in dogs by a prospectively programmed I.V. infusion: infusion pattern and IRI response.
January 1978, Acta diabetologica latina,
Y Omori, and S Minei, and Y Uchigata, and M Shimizu, and M Sanaka, and M Honda, and Y Hirata
Heterogeneity of plasma IRI responses in patients in IGT and diabetes.
September 1980, Diabetologia,
Y Omori, and S Minei, and Y Uchigata, and M Shimizu, and M Sanaka, and M Honda, and Y Hirata
[Borderline type, impaired glucose tolerance (IGT), and impaired fasting glucose (IFG): their concepts, classification and significance].
February 2005, Nihon rinsho. Japanese journal of clinical medicine,
Y Omori, and S Minei, and Y Uchigata, and M Shimizu, and M Sanaka, and M Honda, and Y Hirata
Influence of obesity on glucose tolerance and IRI response.
January 1990, Diabetes research and clinical practice,
Y Omori, and S Minei, and Y Uchigata, and M Shimizu, and M Sanaka, and M Honda, and Y Hirata
The ROC curve in the evaluation of fasting capillary blood glucose as a screening test for diabetes and IGT.
November 1994, Diabetes care,
Y Omori, and S Minei, and Y Uchigata, and M Shimizu, and M Sanaka, and M Honda, and Y Hirata
Glucose, FFA, IRI and GH response to I.V. glibenclamide.
July 1973, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Y Omori, and S Minei, and Y Uchigata, and M Shimizu, and M Sanaka, and M Honda, and Y Hirata
Towards new diagnostic criteria for diagnosing GDM: the HAPO study.
January 2009, Journal of perinatal medicine,
Y Omori, and S Minei, and Y Uchigata, and M Shimizu, and M Sanaka, and M Honda, and Y Hirata
[Definition and diagnosis of IFG, IGT and borderline type].
February 2005, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!